<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Cell Int</journal-id><journal-id journal-id-type="iso-abbrev">Cancer Cell Int</journal-id><journal-title-group><journal-title>Cancer Cell International</journal-title></journal-title-group><issn pub-type="epub">1475-2867</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">31938022</article-id><article-id pub-id-type="pmc">6954602</article-id><article-id pub-id-type="publisher-id">1096</article-id><article-id pub-id-type="doi">10.1186/s12935-020-1096-3</article-id><article-categories><subj-group subj-group-type="heading"><subject>Primary Research</subject></subj-group></article-categories><title-group><article-title>Silencing of miR-17-5p suppresses cell proliferation and promotes cell apoptosis by directly targeting PIK3R1 in laryngeal squamous cell carcinoma</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Jian-Xing</given-names></name><address><email>jianxingwang_2019@163.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Jia</surname><given-names>Xin-Ju</given-names></name><address><email>jiaxinjuwjx@163.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Yan</given-names></name><address><email>liuyan_4h_2019@163.com</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Dong</surname><given-names>Jin-Hui</given-names></name><address><email>dong_jinhui123@126.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ren</surname><given-names>Xiu-Min</given-names></name><address><email>xiuminren@126.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Xu</surname><given-names>Ou</given-names></name><address><email>hebei_xuou@sina.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Sheng-Hui</given-names></name><address><email>liushenghuiemail@163.com</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-8378-5469</contrib-id><name><surname>Shan</surname><given-names>Chun-Guang</given-names></name><address><email>chunguang_2019@163.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1804 3009</institution-id><institution-id institution-id-type="GRID">grid.452702.6</institution-id><institution>Department of Otolaryngology, </institution><institution>The Second Hospital of Hebei Medical University, </institution></institution-wrap>215 Heping West Road, Shijiazhuang, 050000 People&#x02019;s Republic of China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.452458.a</institution-id><institution>Department of Endocrinology, </institution><institution>The First Hospital of Hebei Medical University, </institution></institution-wrap>89 Donggang Road, Shijiazhuang, 050000 People&#x02019;s Republic of China </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1760 8442</institution-id><institution-id institution-id-type="GRID">grid.256883.2</institution-id><institution>Department of Anesthesiology, </institution><institution>The 4th Hospital of Hebei Medical University, </institution></institution-wrap>169 Tianshan Street, Shijiazhuang, 050000 People&#x02019;s Republic of China </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1760 8442</institution-id><institution-id institution-id-type="GRID">grid.256883.2</institution-id><institution>Department of Otolaryngology Head and Neck Surgery, </institution><institution>The 4th Hospital of Hebei Medical University, </institution></institution-wrap>169 Tianshan Street, Shijiazhuang, 050000 People&#x02019;s Republic of China </aff></contrib-group><pub-date pub-type="epub"><day>10</day><month>1</month><year>2020</year></pub-date><pub-date pub-type="pmc-release"><day>10</day><month>1</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>20</volume><elocation-id>14</elocation-id><history><date date-type="received"><day>1</day><month>11</month><year>2019</year></date><date date-type="accepted"><day>2</day><month>1</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2020</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Increasing evidence has suggested that microRNAs (miRNAs) act as key post-transcriptional regulators in tumor progression. Previous studies have confirmed that miR-17-5p functions as an oncogene in multiple cancers and contributes to tumor progression. However, the role and biological functions of miR-17-5p in the development of laryngeal squamous cell carcinoma (LSCC) still remain unknown.</p></sec><sec><title>Methods</title><p id="Par2">qRT-PCR was used to detect miRNA and mRNA expression levels in LSCC tissues and cell lines. CCK-8 assay was used to measure cell viability and flow cytometry was performed to evaluate cell apoptosis. Western blot analysis was used to detect the protein levels of BAX, BCL-2, cleaved Caspase-3, PIK3R1 and AKT. Luciferase reporter assay was used to detect the effect of miR-17-5p on PIK3R1 expression. Xenograft animal model was used to test the effect of miR-17-5p on LSCC cell in vivo.</p></sec><sec><title>Results</title><p id="Par3">In the present study, we found that miR-17-5p expression level was upregulated in LSCC tissues and cell lines. Depletion of miR-17-5p in LSCC cells significantly reduced cell proliferation and promoted cell apoptosis in vitro and in vivo. Mechanically, knockdown of miR-17-5p in LSCC cells inhibited BCL-2 expression while enhanced BAX and cleaved Caspase-3 protein expression. Moreover, depletion of miR-17-5p in LSCC cells suppressed AKT phosphorylation but did not influence PTEN expression. Importantly, miR-17-5p positively regulated PIK3R1 expression by directly binding to its 3&#x02032;-untranslated region (UTR). Additionally, PIK3R1, which expression was downregulated in LSCC tissues and cell lines, was involved in LSCC cell survival by modulating the activation of AKT signal pathway. Dysregulation of miR-17-5p/PIK3R1 axis was participated in LSCC cell proliferation and apoptosis by inhibiting the activation of the PI3K/AKT signaling pathway.</p></sec><sec><title>Conclusions</title><p id="Par4">In conclusion, our study indicates that the miR-17-5p/PIK3R1 axis plays an essential role in the development of LSCC and provides a potential therapeutic target for LSCC treatment.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Laryngeal squamous cell carcinoma</kwd><kwd>miR-17-5p</kwd><kwd>PIK3R1</kwd><kwd>Proliferation</kwd><kwd>Apoptosis</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2020</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par12">Laryngeal squamous cell carcinoma (LSCC) is the most common head and neck malignancy accounting for more than 95% of head and neck squamous cell carcinoma (HNSCC), with 177,422 new cases and 94,771 deaths worldwide in 2018 [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Most of LSCC patients who are diagnosed at early stage may benefit from surgery, followed by radiotherapy and/or chemotherapy [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. However, the 5-year overall survival rate of patients with LSCC who are asymptomatic in the advanced stage remains lower than approximately 50% [<xref ref-type="bibr" rid="CR5">5</xref>]. Therefore, an understanding of the driven-element and molecular mechanisms of tumorigenesis in LSCC is crucial.</p><p id="Par13">microRNAs (miRNAs) are the most important post-transcriptional regulators which suppress the expression of protein-coding genes by directly targeting mRNA at the 3&#x02032;-untranslated region (UTR) for translational repression or degradation [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. Accumulating studies have shown that miRNAs are implicated in LSCC development, including proliferation, apoptosis, migration and invasion [<xref ref-type="bibr" rid="CR8">8</xref>&#x02013;<xref ref-type="bibr" rid="CR10">10</xref>]. Our previous study has confirmed that miR-486 is involved in LSCC cell migration by targeting FLNA [<xref ref-type="bibr" rid="CR11">11</xref>]. Moreover, miR-370, which functions as a tumor suppressor, participates in LSCC cell growth by inducing FOXM1 expression [<xref ref-type="bibr" rid="CR12">12</xref>]. Overexpression of miR-613 reduces LSCC cell proliferation, invasion, and blocks G1/S phase transition by targeting the PDK1 gene [<xref ref-type="bibr" rid="CR13">13</xref>]. Furthermore, miR-1297, miR-143-3p, miR-503 and miR-205 also promote LSCC cell progression [<xref ref-type="bibr" rid="CR14">14</xref>&#x02013;<xref ref-type="bibr" rid="CR17">17</xref>]. Recent studies have confirmed that miR-17-5p plays critical roles in tumor progression, such as pancreatic cancer, breast cancer, hepatocellular carcinoma, gastric cancer and prostate cancer [<xref ref-type="bibr" rid="CR18">18</xref>&#x02013;<xref ref-type="bibr" rid="CR22">22</xref>]. However, the expression and biological functions of miR-17-5p in LSCC remain unclear.</p><p id="Par14">Increasing evidence has revealed that abnormal activation of PI3K/AKT pathway is associated with the generation of multiple tumors, including LSCC, via regulating cell survival, apoptosis, proliferation, migration, invasion and vesicle trafficking [<xref ref-type="bibr" rid="CR23">23</xref>&#x02013;<xref ref-type="bibr" rid="CR25">25</xref>]. PIK3R1, which encodes the p85&#x003b1; protein, is best known as the regulatory subunit of class 1A PI3Ks through its interaction, stabilization and repression of PI3K-p110 catalytic subunits [<xref ref-type="bibr" rid="CR26">26</xref>]. PIK3R1 has been identified to be differentially expressed in many human cancers. For example, PIK3R1 functions as a tumor suppressor in hepatocellular carcinomas and renal cancer [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>], whereas acts as an oncogene in ovarian and colon tumors and plays a role in tumor progression and metastasis [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. However, the relationship between PIK3R1 and LSCC cell development has not been fully elucidated.</p><p id="Par15">In the present study, we observed an increased level of miR-17-5p in LSCC tissues and cell lines. Knockdown of miR-17-5p reduced LSCC cell proliferation and induced apoptosis in vitro and in vivo by suppressing the activation of the PI3K/AKT pathway. Importantly, we demonstrated miR-17-5p positively regulated PIK3R1 mRNA and protein expression by targeting its 3&#x02032;UTR. In addition, PIK3R1 may function as tumor suppressor in LSCC by promoting cell growth. Taken together, our findings indicate that the miR-17-5p/PIK3R1/AKT pathway plays a key role in LSCC proliferation and apoptosis, providing a potential therapeutic target for LSCC treatment.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Patients and samples</title><p id="Par16">39 LSCC samples and non-cancerous adjacent normal tissues were obtained from the Department of Otolaryngology, Second Hospital of Hebei Medical University between September 2017 and July 2018. None of the LSCC patients were treated with radiotherapy or chemotherapy before surgery. All tissues were immediately frozen in liquid nitrogen after surgery and then later stored at &#x02212;&#x02009;80&#x000a0;&#x000b0;C for following use. This study was approved by Ethics Committee of Second Hospital of Hebei Medical University. The written informed consent was obtained from every patient. All the experiments in this paper obey World Medical Association Declaration of Helsinki.</p></sec><sec id="Sec4"><title>Cell culture and transfection</title><p id="Par17">The human LSCC cell lines (Hep2, SCC-2 and SCC-40) and the normal human oral keratinocyte cell line (HOK) were maintained in our lab. All cells were cultured in RPMI-1640 (Gibco, Beijing, China) with 10% fetal bovine serum (FBS) (Clark Bio, Claymont, DE), 100&#x000a0;units/ml penicillin and 100&#x000a0;&#x003bc;g/ml streptomycin and were incubated at 37&#x000a0;&#x000b0;C in a humidified incubator with 5% CO<sub>2</sub>. The miR-17-5p mimic, mimic-negative control (NC), miR-17-5p inhibitor and inhibitor-negative control (NC) were purchased from GenePharma Co., Ltd (Shanghai, China). Overexpression plasmid of PIK3R1 (pcDNA3.1-PIK3R1) and luciferase reporter vector were purchased from GENEWIZ Company (Suzhou, China). Cell transfections were carried out by using Lipofectamine 2000 (Invitrogen) according to the manufacturer&#x02019;s protocol.</p></sec><sec id="Sec5"><title>Cell proliferation assay</title><p id="Par18">Cell proliferation assay was detected by using a Cell Counting Kit-8 (CCK-8, Dojindo Laboratory, Kyushu, Japan) according to the manufacturer&#x02019;s protocol. Briefly, LSCC cells were seeded in 96-well plates and then transfected with miR-17-5p inhibitor or pcDNA3.1-PIK3R1 respectively or co-transfected with them both for 72&#x000a0;h. At the indicated times, 10&#x000a0;&#x003bc;l CCK-8 solution was added into each well for another 3&#x000a0;h. Finally, the absorbance was measured at 450&#x000a0;nm by using a microplate reader (Thermo Fisher USA).</p></sec><sec id="Sec6"><title>Cell apoptosis analysis</title><p id="Par19">Cell apoptosis was detected by using the Annexin V-FITC/PI apoptosis detection kit (BD Biosciences, USA) following the manufacturer&#x02019;s instructions. Briefly, after transfection, cells were grown in 6-well plates for 48&#x000a0;h. Then cells were harvested and washed with ice-cold PBS thrice. Then, the cells were stained with Annexin V-fluorescein isothiocyanate and PI. The data analysis was performed using BD FACS Diva software (BD, USA).</p></sec><sec id="Sec7"><title>Xenograft animal model</title><p id="Par20">All animal studies were approved by the Institutional Animal Care Committee of Hebei Medical University. 6&#x000a0;weeks&#x02019; old BALB/C nude mice were purchased from Vital River Laboratory Animal Technology Co., Ltd. (Beijing, China). 1&#x02009;&#x000d7;&#x02009;10<sup>7</sup> LV-anti-miR-17-5p or LV-anti-miR-NC-infected Hep2 cells were resuspended in 100&#x000a0;&#x003bc;l PBS mixed with 100&#x000a0;&#x003bc;l Matrigel (356234. BD, MA, USA); The suspension of cells was injected subcutaneously into the left dorsal flanks. The volume of xenograft was measured every 3&#x000a0;days. At the end of the experiment, the mice were euthanized by carbon dioxide asphyxiation. The tumor tissues were stored in liquid nitrogen immediately and stored at &#x02212;&#x02009;80&#x000a0;&#x000b0;C for western blot or qRT-PCR analysis.</p></sec><sec id="Sec8"><title>RNA extraction and quantitative real-time PCR</title><p id="Par21">Total RNA from tissues and cultured cells were extracted by using QIAzol Lysis Reagent (79306) according to the manufacturer&#x02019;s protocol. For microRNA analysis, the miScripIIRT kit (QIAGEN GmbH, D-40724 Hilden, Germany) was used for reverse transcription, and the miScript SYBR<sup>&#x000ae;</sup> Green PCR kit was used for qRT-PCR with specific primers for microRNAs. RNU6b (U6) was used as internal control. For mRNA analysis, total cellular RNA was reverse-transcribed to first strand cDNA by using M-MLV First Strand Kit (Life Technologies). And Platinum SYBR Green qPCR Super Mix UDG Kit (Invitrogen) was used for the qRT-PCR of mRNAs. The mRNA expression was normalized to &#x003b2;-actin.</p></sec><sec id="Sec9"><title>Luciferase assay</title><p id="Par22">Luciferase assay was performed as previously described [<xref ref-type="bibr" rid="CR31">31</xref>]. Briefly, Hep2 cells were seeded into a 24-well plate, miR-17-5p mimic (or mimic-NC) was co-transfected with PIK3R1 reporter construct (wild-type or mutant) or the empty vector using Lipofectamine&#x02122; 2000 reagent for 48&#x000a0;h. Then the transfected cells were harvested in lysis buffer and detected by Dual-Glo Luciferase Assay System (Promega, Madison, WI) according to the manufacturer&#x02019;s protocols. Firefly luciferase (FLuc) activity was measured and normalized against the Renilla luciferase (RLuc) activity.</p></sec><sec id="Sec10"><title>Western blot analysis</title><p id="Par23">The tissues and cultured cells were lysed with RIPA buffer. The protein was collected for western blot analysis. Equal amounts of protein were run on 10% SDS-PAGE, and electro-transferred to a polyvinylidene fluoride (PVDF) membranes (Millipore). The specific primary antibodies as follows: anti-PIK3R1 (1:1000, abcam, ERP18702), anti-PTEN (1:1000, abcam ab32199), anti-caspase 3 (1:1000, abcam, ab13847), anti-pan-AKT (1:1000, abcam, ab8805), anti-p-AKT (phospho T308) (1:1000, abcam, ab38449), anti-BCL-2 (1:1000, Proteintech, 12,789-1-AP), anti-BAX (1:1000, Proteintech, 50,599-2-Ig) or anti-&#x003b2;-actin (1:1000, Proteintech, 60,008-1-Ig). The memberanes were visualized with Immobilon ECL (Millipore). FusionCapt Advance Fx5 software (Vilber Lourmat) was used to capture the images.</p></sec><sec id="Sec11"><title>Target prediction</title><p id="Par24">Potential target genes of miR-17-5p were identified with following miRNA target prediction algorithms: Targetscan (<ext-link ext-link-type="uri" xlink:href="http://www.targetcan.org/mmu_71/">http://www.targetcan.org/mmu_71/</ext-link>).</p></sec><sec id="Sec12"><title>Statistical analysis</title><p id="Par25">All of the data were represented as the mean&#x02009;&#x000b1;&#x02009;S.E.M. Independent Student&#x02019;s t-test was used for comparisons of differences between two groups. Results were considered statistically significant at <italic>P&#x02009;</italic>&#x0003c;&#x02009;0.05. Graphpad Prism 7.0 software was using to perform the statistical analysis (GraphPad Software, San Diego, CA, USA).</p></sec></sec><sec id="Sec13"><title>Results</title><sec id="Sec14"><title>miR-17-5p is upregulated in LSCC tissues and cell lines</title><p id="Par26">To investigate the role of miR-17-5p in LSCC development, we first sought to know the level of miR-17-5p in LSCC tissues. Hematoxylin and eosin staining was used to distinguish the normal laryngeal tissues and the LSCC tissues (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>a). qRT-PCR result showed that miR-17-5p level was significantly upregulated in LSCC tissues (n&#x02009;=&#x02009;39) compared with that in adjacent normal tissues (n&#x02009;=&#x02009;39) (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>b). We also found that miR-17-5p level was much higher in LSCC tissues from patients with LSCC in T 3/4 stage (n&#x02009;=&#x02009;16) than that from patients in T 1/2 stage (n&#x02009;=&#x02009;23) (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>c). Furthermore, higher miR-17-5p expression levels were maintained in LSCC tissues from patients in III/IV stage (n&#x02009;=&#x02009;24) than that in II/III stage (n&#x02009;=&#x02009;15) (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>d). Importantly, we found that patients with higher expression levels of miR-17-5p in LSCC tissues had poor survival rates compared with the patients who had a lower expression level of miR-17-5p (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>e). Moreover, we detected the miR-17-5p expression levels in different LSCC cell lines (SCC-2, SCC-40 and Hep2) compared with that in human oral keratinocyte cell line HOK. The result showed that miR-17-5p level was increased in Hep2 and SCC-2 cells but not in SCC-40 cells (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>f). These results suggest that the miR-17-5p is upregulated in LSCC and may correlated with LSCC progression.<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>miR-17-5p is upregulated in LSCC tissues and LSCC cell lines. <bold>a</bold> Hematoxylin and eosin staining of normal laryngeal tissues and LSCC tissues. <bold>b</bold> qRT-PCR was used to detected miR-17-5p expression level in LSCC tissues (n&#x02009;=&#x02009;39) and adjacent normal tissues (n&#x02009;=&#x02009;39). Normalized to U6. **<italic>P&#x02009;</italic>&#x0003c;&#x02009;0.01 vs. normal tissues. <bold>c</bold> qRT-PCR was used to detect the miR-17-5p expression level in the tissues from patients with LSCC in T 3/4 stage (n&#x02009;=&#x02009;16) and the tissues from patients in T 1/2 stage (n&#x02009;=&#x02009;23). *<italic>P&#x02009;</italic>&#x0003c;&#x02009;0.05 vs. T 1/2 stage. <bold>d</bold> qRT-PCR was used to detect miR-17-5p expression level in tissues from patients with LSCC in TNM I/II stage (n&#x02009;=&#x02009;15) and in III/IV stage (n&#x02009;=&#x02009;24). *<italic>P&#x02009;</italic>&#x0003c;&#x02009;0.05 vs. TNM I/II stage. <bold>e</bold> Kaplan&#x02013;Meier analysis was used to analyze the survival rate of LSCC patients with low or high miR-17-5p level. <bold>f</bold> qRT-PCR was used to detect miR-17-5p expression level in three LSCC cell lines (SCC-2, SCC-40 and Hep2) compared with human oral keratinocyte cell line HOK. *<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05, **<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01 vs. HOK cell</p></caption><graphic xlink:href="12935_2020_1096_Fig1_HTML" id="MO1"/></fig>
</p></sec><sec id="Sec15"><title>Depletion of miR-17-5p inhibits cell proliferation and promotes cell apoptosis in LSCC in vitro</title><p id="Par27">Previous studies have reported that miR-17-5p acts as an onco-miRNA implicated in multiple types of cancers, therefore, we wanted to investigate whether miR-17-5p is involved in LSCC cell survival. First, we transfected miR-17-5p inhibitor or negative control (NC) into Hep2 cells and SCC-2 cells in order to knockdown the miR-17-5p expression in LSCC cells. qRT-PCR results showed that transfection of miR-17-5p inhibitor into LSCC cell lines dramatically decreased the miR-17-5p level compared with negative control (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>a). Then CCK-8 assay was used to detect cell viability. We found that depletion of miR-17-5p in SCC-2 cells significantly inhibited cell proliferation. This result was further confirmed in Hep2 cells (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>b). In addition, suppression of miR-17-5p by transfection of miR-17-5p inhibitor in SCC-2 cells and Hep2 cells obviously increased cell apoptosis compared with negative control by flow cytometry-based Annexin V/PI assay (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>c). These findings reveal that miR-17-5p may act as an onco-miRNA and is involved in cell proliferation and apoptosis in LSCC cells.<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Depletion of miR-17-5p inhibits cell proliferation and promotes cell apoptosis in LSCC in vitro. <bold>a</bold> Hep2 cells and SCC-2 cells were transfected with miR-17-5p inhibitor or inhibitor-NC. miR-17-5p expression was detected by using qRT-PCR. ***<italic>P&#x02009;</italic>&#x0003c;&#x02009;0.001 vs. inhibitor-NC. <bold>b</bold> Cells were treated as (<bold>a</bold>), cell viability was measured by using CCK-8 assay in different times. Data shown are mean&#x02009;&#x000b1;&#x02009;standard deviation of three independent experiments. *<italic>P&#x02009;</italic>&#x0003c;&#x02009;0.05, **<italic>P&#x02009;</italic>&#x0003c;&#x02009;0.01, ***<italic>P&#x02009;</italic>&#x0003c;&#x02009;0.001 vs. inhibitor-NC. <bold>c</bold> Cells were treated as (<bold>a</bold>) for 48&#x000a0;h. Cell apoptosis was assessed by Annexin V-FITC/PI staining. Right panel shows the apoptosis rate of three independent experiments. **<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01, ***<italic>P&#x02009;</italic>&#x0003c;&#x02009;0.001 vs. inhibitor-NC</p></caption><graphic xlink:href="12935_2020_1096_Fig2_HTML" id="MO2"/></fig></p></sec><sec id="Sec16"><title>Depletion of miR-17-5p suppresses AKT phosphorylation</title><p id="Par28">To further investigate the underlying mechanism of the effect of miR-17-5p on LSCC cell proliferation and apoptosis, we first transfected Hep2 cells and SCC-2 cells with miR-17-5p inhibitor. Western blot analysis was used to measure the protein levels of proliferation maker protein BAX, anti-apoptotic marker BCL-2 and apoptotic maker cleaved Caspase-3. As shown in Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>a, knockdown of miR-17-5p in both cells increased BAX and cleaved Caspase-3 protein levels while reduced BCL-2 protein level. qRT-PCR results also confirmed that transfection of miR-17-5p inhibitor into SCC-2 and Hep2 cells increased BAX mRNA expression level whereas decreased BCL-2 mRNA level (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>b). Given that BAX and BCL-2 are the important downstream genes of PI3K/AKT pathway, which is involved in cell proliferation, apoptosis and cell cycle, we next investigated whether miR-17-5p regulates BAX/BCL-2 expression by modulating the activation of PI3K/AKT pathway. As shown in Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>c, depletion of miR-17-5p in Hep2 cells and SCC-2 cells suppressed the phosphorylated AKT (p-AKT) protein level. However, the tension homology deleted on chromosome 10 (PTEN) protein level was not changed significantly, indicating that the miR-17-5p may modulate the AKT phosphorylation (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>d). These results demonstrate that knockdown of miR-17-5p may inhibit AKT phosphorylation and influence the activation of PI3K/AKT pathway.<fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>Depletion of miR-17-5p suppresses AKT phosphorylation. <bold>a</bold> Hep2 cells and SCC-2 cells were transfected with miR-17-5p inhibitor or inhibitor-NC. Western blot analysis was used to detect the protein levels of BCL-2, BAX, cleaved Caspase-3. Right panel shows densitometric analysis. *<italic>P&#x02009;</italic>&#x0003c;&#x02009;0.05, **<italic>P&#x02009;</italic>&#x0003c;&#x02009;0.01 vs. inhibitor-NC. <bold>b</bold> Cells were treated as (<bold>a</bold>), mRNA levels of BCL-2 and BAX were detected by using qRT-PCR. Normalized against &#x003b2;-actin. **<italic>P&#x02009;</italic>&#x0003c;&#x02009;0.01, ***<italic>P&#x02009;</italic>&#x0003c;&#x02009;0.001 vs. inhibitor-NC. <bold>c</bold> Cells were treated as (<bold>a</bold>), protein levels of p-AKT and AKT were detected by western blot analysis. Right panel shows densitometric analysis. **<italic>P&#x02009;</italic>&#x0003c;&#x02009;0.01 vs. inhibitor-NC. <bold>d</bold> Cells were treated as (<bold>a</bold>), PTEN protein level was detected by western blot analysis. Right panel shows densitometric analysis</p></caption><graphic xlink:href="12935_2020_1096_Fig3_HTML" id="MO3"/></fig>
</p></sec><sec id="Sec17"><title>PIK3R1 is a direct target of miR-17-5p</title><p id="Par29">To elucidate the underlying mechanism of the regulation of PI3K/AKT pathway by miR-17-5p, we predicted to the target genes of miR-17-5p by TargetScan (<ext-link ext-link-type="uri" xlink:href="http://www.targetscan.org">http://www.targetscan.org</ext-link>). According to the candidate genes, PIK3R1 aroused our attention. PIK3R1, as the subunit of PI3K, which plays a critical role in the activation of PI3K pathway by binding and stabilizing PI3K p110 catalytic subunit, influenced downstream of AKT and disturbance in the balance between cell apoptosis and proliferation. We found that there exists a putative miR-17-5p-binding site in the PIK3R1 3&#x02032;-UTR (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>a). To further confirm the relationship between miR-17-5p and PIK3R1, we constructed dual-luciferase reporters including the wild-type or mutant 3&#x02032; UTR of PIK3R1 and assessed luciferase reporter assay. First, we overexpressed miR-17-5p in Hep2 cells with transfection of miR-17-5p mimic. As shown in Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>b, transfection of miR-17-5p into Hep2 cells markedly increased miR-17-5p expression compared with negative control. Then dual-luciferase reporter assay was performed. To do this, Hep2 cells co-transfected with PIK3R1-3&#x02032;UTR-reporter plasmid containing the miR-17-5p-binding site (wt or mut) and miR-17-5p mimic. As shown in Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>c, miR-17-5p mimic significantly decreased luciferase activity mediated by wild-type 3&#x02032;-UTR but had no effect on the luciferase activity mediated by its mutant. Next, we performed the loss and gain experiments to determine whether miR-17-5p influence PIK3R1 expression. As shown in Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>d overexpression of miR-17-5p in Hep2 cells obviously reduced while knockdown of miR-17-5p induced PIK3R1 protein level compared with negative control. Constantly, p-AKT protein level was significantly downregulated in the Hep2 cells after transfecting with miR-17-5p inhibitor while upregulated after transfecting with miR-17-5p mimic. In addition, transfection of miR-17-5p mimic in Hep2 cells significantly decreased PIK3R1 mRNA level compared with mimic-NC. Conversely, transfection of miR-17-5p inhibitor could increase PIK3R1 mRNA expression (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>e). These results show that miR-17-5p negatively regulates PIK3R1 level by directly targeting its 3&#x02032;UTR.<fig id="Fig4"><label>Fig.&#x000a0;4</label><caption><p>PIK3R1 is a direct target of miR-17-5p. <bold>a</bold> Potential binding site of miR-17-5p at the 3&#x02032; UTR of PIK3R1 mRNA. <bold>b</bold> Hep2 cells were transfected with miR-17-5p mimic or mimic-NC. The miR-17-5p expression level was detect by using qRT-PCR. ***<italic>P&#x02009;</italic>&#x0003c;&#x02009;0.001 vs. mimic-NC. <bold>c</bold> Hep2 cells were co-transfected with miR-17-5p mimic or mimic-NC and luciferase reporter plasmid containing wild-type or mutated miR-17-5p-binding site (mut) at PIK3R1 3&#x02032;-UTR. Luciferase reporter assay was used to detect luciferase activity. **<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01 vs. mimic-NC. <bold>d</bold> Hep2 cells were transfected with miR-17-5p mimic, miR-17-5p inhibitor or negative control. Western blot analysis was used to detect protein expression levels of PIK3R1, AKT and p-AKT. Right panel shows densitometric analysis. *<italic>P&#x02009;</italic>&#x0003c;&#x02009;0.05, **<italic>P&#x02009;</italic>&#x0003c;&#x02009;0.01 vs. corresponding negative control. <bold>e</bold> Cells were treated as (<bold>d</bold>), PIK3R1 mRNA level was detected by using qRT-PCR. *<italic>P&#x02009;</italic>&#x0003c;&#x02009;0.05, **<italic>P&#x02009;</italic>&#x0003c;&#x02009;0.01 vs. corresponding negative control</p></caption><graphic xlink:href="12935_2020_1096_Fig4_HTML" id="MO4"/></fig>
</p></sec><sec id="Sec18"><title>PIK3R1 is downregulated in LSCC tissues and cell lines</title><p id="Par30">To measure the expression level of PIK3R1 in LSCC, we then examined the mRNA level of PIK3R1 in LSCC tissues. qRT-PCR result showed that mRNA level of PIK3R1 was markedly lower in LSCC tissues (n&#x02009;=&#x02009;39) than that in normal tissues (n&#x02009;=&#x02009;39) (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>a). Similarly, the LSCC tissues had a lower protein level of PIK3R1 than normal tissues (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>b). Moreover, we measured the expression level of PIK3R1 in different LSCC cell lines compared with that in human oral keratinocyte cell line HOK. As shown in Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>c, the mRNA level of PIK3R1 was decreased in Hep2 and SCC-2 cells but not in SCC-40 cells. Consistently, Hep2 cells and SCC-2 cells had a lower protein level of PIK3R1 (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>d). Additionally, the correlation analysis also revealed that there was a negative correlation between miR-17-5p and PIK3R1 in LSCC tissues (P&#x02009;=&#x02009;0.0100, R&#x02009;=&#x02009;&#x02212;&#x02009;0.4852) (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>e). These findings indicate that PIK3R1 expression is reduced in LSCC tissues and cell lines.<fig id="Fig5"><label>Fig.&#x000a0;5</label><caption><p>PIK3R1 is downregulated in LSCC tissues and cell lines. <bold>a</bold> qRT-PCR was used to detect the mRNA level of PIK3R1 in LSCC tissues (n&#x02009;=&#x02009;39) and adjacent normal tissues (n&#x02009;=&#x02009;39). *<italic>P&#x02009;</italic>&#x0003c;&#x02009;0.05 vs. normal tissues. <bold>b</bold> Western blot analysis was used to detect the protein level of PIK3R1 in LSCC tissues and adjacent normal tissues. The representative experiments were present. <bold>c</bold> qRT-PCR was used to detect PIK3R1 mRNA expression in three LSCC cell lines (SCC-2, SCC-40 and Hep2) compared with human oral keratinocyte cell line HOK. *<italic>P&#x02009;</italic>&#x0003c;&#x02009;0.05, **<italic>P&#x02009;</italic>&#x0003c;&#x02009;0.01 vs. HOK cell. <bold>d</bold> Western blot analysis was used to detect PIK3R1 protein level in three LSCC cell lines (SCC-2, SCC-40 and Hep2) compared with human oral keratinocyte cell line HOK. The representative experiments were present. <bold>e</bold> Pearson correlation was used to analyze the relationship between miR-17-5p and PIK3R1 mRNA (R&#x02009;=&#x02009;&#x02212;&#x02009;0.4852, P&#x02009;=&#x02009;0.0100)</p></caption><graphic xlink:href="12935_2020_1096_Fig5_HTML" id="MO5"/></fig>
</p></sec><sec id="Sec19"><title>miR-17-5p/PIK3R1 axis plays an essential role in LSCC cell proliferation</title><p id="Par31">To investigate whether miR-17-5p participated in LSCC cell proliferation by regulating PIK3R1 expression, we wanted to know the effect of PIK3R1 in LSCC cell growth. Because Hep2 cells had a much higher PIK3R1 mRNA expression level, we chose it for the following experiment. First, we conducted the overexpression plasmid of PIK3R1 (pcDNA3.1-PIK3R1) and transfected it into Hep2 cells. qRT-PCR and western blot analysis results showed that transfection of pcDNA3.1-PIK3R1 could significantly increase the PIK3R1 protein and mRNA level compared with empty vector, indicating that pcDNA3.1-PIK3R1 had a higher efficiency in increasing expression of PIK3R1 in Hep2 cells (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>a, b). Then the functional experiments revealed that overexpression of PIK3R1 significantly decreased the cell viability while increased the apoptosis in Hep2 cells (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>c lane 2 and d). Western blot analysis also showed that overexpression of PIK3R1 in Hep2 cells decreased the protein levels of BCL-2 and p-AKT whereas increased protein levels of cleaved Caspase-3 and BAX (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>e lane 2). Additionally, we performed the rescued experiments to demonstrate whether PIK3R1 mediating miR-17-5p and LSCC cell proliferation and apoptosis. Apoptosis analysis showed that overexpression of PIK3R1 in Hep2 cells promoted cell apoptosis and this effect could enforced by co-transfected with miR-17-5p inhibitor in Hep2 cells (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>c). CCK-8 assay result also showed that overexpression of PIK3R1 combination with knockdown of miR-17-5p in Hep2 cell had a much lower growth ability compared with overexpression of PIK3R1 alone (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>d). Thereafter, overexpression of PIK3R1 in Hep2 cell decreased the protein levels of BCL-2 and p-AKT. This inhibitory effect could be enhanced by co-transfection of pcDNA3.1-PIK3R1 and miR-17-5p inhibitor in Hep2 cells. Consistently, co-transfection of pcDNA3.1-PIK3R1 and miR-17-5p inhibitor in Hep2 cells increased BAX and cleaved Caspase-3 protein level compared with overexpression of PIK3R1 alone (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>e). Taken together, these findings indicate PIK3R1/miR-17-5p play an important role in LSCC cell apoptosis and proliferation.<fig id="Fig6"><label>Fig.&#x000a0;6</label><caption><p>miR-17-5p/PIK3R1 axis plays an essential role in LSCC cell proliferation. <bold>a</bold> Hep2 cells were transfected with pcDNA3.1-PIK3R1 or empty vector. The mRNA level of PIK3R1 was detected by qRT-PCR. ***<italic>P&#x02009;</italic>&#x0003c;&#x02009;0.001 vs. empty vector. <bold>b</bold> Hep2 cells were treated as (<bold>a</bold>), the protein level of PIK3R1 was detected by western blot analysis. **<italic>P&#x02009;</italic>&#x0003c;&#x02009;0.01 vs. empty vector. <bold>c</bold> Hep2 cells were transfected with pcDNA3.1-PIK3R1 and miR-17-5p inhibitor respectively or transfected them together. Cell apoptosis was detected by Annexin V-FITC/PI staining. Below panel shows the analysis of apoptosis rate. **<italic>P&#x02009;</italic>&#x0003c;&#x02009;0.01, ***<italic>P&#x02009;</italic>&#x0003c;&#x02009;0.001 vs. corresponding negative control; <sup>#</sup><italic>P&#x02009;</italic>&#x0003c;&#x02009;0.05 vs. pcDNA3.1-PIK3R1. <bold>d</bold> Hep2 cells were treated as (<bold>c</bold>), cell viability was detected by CCK-8 assay in different times. **<italic>P&#x02009;</italic>&#x0003c;&#x02009;0.01 vs. corresponding negative control; <sup>#</sup><italic>P&#x02009;</italic>&#x0003c;&#x02009;0.05 vs. pcDNA3.1-PIK3R1. <bold>e</bold> Hep2 cells were treated as (<bold>c</bold>), the protein levels of PIK3R1, BCL-2, BAX, cleaved Caspase-3, p-AKT and AKT were detected by western blot analysis. Below panel shows densitometric analysis. *<italic>P&#x02009;</italic>&#x0003c;&#x02009;0.05, **<italic>P&#x02009;</italic>&#x0003c;&#x02009;0.01 vs. corresponding negative control; <sup>#</sup><italic>P&#x02009;</italic>&#x0003c;&#x02009;0.05 vs. pcDNA3.1-PIK3R1</p></caption><graphic xlink:href="12935_2020_1096_Fig6_HTML" id="MO6"/></fig>
</p></sec><sec id="Sec20"><title>miR-17-5p is involved in LSCC proliferation in vivo</title><p id="Par32">To validate the pathophysiological role of the miR-17-5p in LSCC tumorigenesis, we established LSCC nude mouse xenograft model. To do this, we implanted Hep2 cells with stably knocked down of miR-17-5p (LV-anti-miR-17-5p) or normal Hep2 cells into nude mice. The tumor volume was measured every 3&#x000a0;days. As we expected, depletion of miR-17-5p resulted in smaller tumor volumes compared with negative control group (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>a, b). Consistent with tumor volume, the mean wet weight of the tumors was significantly lower in mice that received miR-17-5p depleted cells than in the control group (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>c). qRT-PCR result showed that the PIK3R1 mRNA expression level was increased in miR-17-5p-depleted group compared with that in the control group (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>d). Moreover, western blot analysis demonstrated that knockdown of miR-17-5p significantly downregulated protein level of BCL-2 and was accompanied by an increase in protein levels of PIK3R1, BAX and cleaved Caspase-3 compared with control group (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>e). These results suggest that knockdown of miR-17-5p inhibits LSCC growth in vivo.<fig id="Fig7"><label>Fig.&#x000a0;7</label><caption><p>miR-17-5p is involved in LSCC proliferation in vivo. Hep2 cells engineered to stably knockdown of miR-17-5p (LV-anti-miR-17-5p) or negative control (LV-anti-miR-NC). Then cells were injected subcutaneously in 200&#x000a0;&#x003bc;l 1640/Matrigel (100:100) into the left posterior ankle of the nude mice to establish xenograft tumors (each group n&#x02009;=&#x02009;6). <bold>a</bold> Images of tumors excised from each group of mice at the final time point (28&#x000a0;days after injection) and the hematoxylin and eosin staining of xenograft tumor. <bold>b</bold> Tumor volumes were monitored by direct measurement with calipers and calculated by the formula: (length&#x02009;&#x000d7;&#x02009;width<sup>2</sup>)/2. *<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05, **<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01 vs. LV-ant-miR-NC. <bold>c</bold> Average weight of tumors in nude mice. *<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 vs. LV-anti-miR-NC. <bold>d</bold> RNA was extracted from excised tumors and the mRNA level of PIK3R1 was detected by using qRT-PCR. **<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01 vs. LV-anti-miR-NC. <bold>e</bold> Total proteins were extracted from excised tumors and the protein levels of PIK3R1, BCL-2, BAX and cleaved Caspase-3 protein were determined by western blotting. Right panel shows densitometric analysis. *<italic>P&#x02009;</italic>&#x0003c;&#x02009;0.05, **<italic>P&#x02009;</italic>&#x0003c;&#x02009;0.01 vs. LV-anti-miR-NC</p></caption><graphic xlink:href="12935_2020_1096_Fig7_HTML" id="MO7"/></fig>
</p></sec></sec><sec id="Sec21"><title>Discussion</title><p id="Par33">Dysregulation of signaling pathways has been identified to play a crucial role in initiating and maintaining malignant phenotypes of tumors [<xref ref-type="bibr" rid="CR32">32</xref>]. In the last decade, studies have demonstrated that uncontrolled activation of PI3K/AKT signaling pathway may be the most frequent driving events involved in development and progression of various cancers, including ovarian cancer, cervical cancer, gastric cancer, glioblastoma, hematological malignant and head and neck cancer [<xref ref-type="bibr" rid="CR32">32</xref>]. PI3K, containing a catalytic subunit (p110) and a regulatory subunit (p85), regulates the downstream phosphorylation of AKT gene, which is involved in promoting cell survival and proliferation by activating the downstream pathways [<xref ref-type="bibr" rid="CR33">33</xref>]. p85, which is encoded by PIK3R1, plays a critical role in the activation of PI3K/AKT pathway by binding and stabilizing PI3K p110 catalytic subunit [<xref ref-type="bibr" rid="CR34">34</xref>]. Therefore, aberrations of PIK3R1, such as gene mutations or downregulation, may play a role in different oncogenic mechanisms and influence distinct downstream signaling processes of AKT pathway. For example, PIK3R1 expression level is markedly downregulated in ovarian cancer, lung cancer, prostate cancer, liver, breast and kidney cancers [<xref ref-type="bibr" rid="CR34">34</xref>]. Moreover, the lower level of PIK3R1 is associated with a poor survival rate in patients with breast cancer [<xref ref-type="bibr" rid="CR35">35</xref>]. Further, lower mRNA level of PIK3R1 is a high-risk factor in stage I non-small cell lung cancers [<xref ref-type="bibr" rid="CR36">36</xref>]. Similarly, downregulation of PIK3R1 mRNA expression is involved in migration and invasion of breast cancer cell in vitro [<xref ref-type="bibr" rid="CR37">37</xref>]. Importantly, silencing of PIK3R1 in breast cancer could enhance the sensitivity to rapamycin [<xref ref-type="bibr" rid="CR38">38</xref>]. In the present study, we first confirmed that the levels of PKI3R1 mRNA and protein were significantly downregulated in LSCC tissues and cell lines. Functional experiments revealed that overexpression of PIK3R1 in LSCC cells obviously induced cell apoptosis and reduced cell proliferation. Moreover, overexpression of PIK3R1 in LSCC cells influenced AKT phosphorylation and the levels of downstream genes, such as BAX, BCL-2 and cleaved Caspases-3. These findings indicate that PIK3R1 can potentially be a biomarker and a target of treatment in LSCC. However, whether PIK3R1 level correlate with prognosis of patients with LSCC needs to be clarified with more clinical trials.</p><p id="Par34">In addition to the effect of mutations in PIK3R1 that disrupt function, there are other different factors that affect the gene expression of PIK3R1. miRNAs, as a family of non-coding RNAs, have been widely accepted as regulators of PIK3R1 expression at the post-transcriptional level. For example, miR-479-5p directly targets PIK3R1 in gastric cancer cell and increases cell growth in vitro [<xref ref-type="bibr" rid="CR39">39</xref>]. miR-486-5p, suppresses cell proliferation in non-small cell lung cancer by regulating PIK3R1 expression and modulating AKT pathway activation [<xref ref-type="bibr" rid="CR40">40</xref>]. Furthermore, PIK3R1 level is reduced by miR-16-5p, which inhibits cell cycle and enhances cell apoptosis by modulating of the PI3K/AKT/NF-KB pathway [<xref ref-type="bibr" rid="CR41">41</xref>]. Besides, miR-495, miR-106a-5p, miR-455 and miR-15 were directly or indirectly contribute to the regulation of PIK3R1 expression [<xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR43">43</xref>]. In the present study, we demonstrated that miR-17-5p could bind to PIK3R1 3&#x02032;UTR directly. Overexpression of miR-17-5p could effectively decrease while knockdown of miR-17-5p increase the mRNA and protein levels of PIK3R1 and influence AKT phosphorylation. Moreover, protein levels of downstream targets known to play roles in cell proliferation and apoptosis including BCL-2, BAX, and cleaved Caspase-3 which were influenced by overexpression of miR-17-5p. Silencing of miR-17-5p enhanced the effect of PIK3R1 overexpression on cell proliferation and apoptosis. In addition, we found a negative relationship between miR-17-5p expression level and PIK3R1 mRNA level in LSCC tissues, indicating that dysregulation of the miR-17-5p/PIK3R1 regulatory pathway may be associated with LSCC cell survival.</p><p id="Par35">It is well known that one miRNA may regulate different target genes, whereas one gene may be affected by multiple miRNAs. miR-17-5p acts as an oncogene in different cancers by specifically binding to and interfering with different targets. For example, miR-17-5p is overexpressed in gastric cancer tissues and cell lines. Knockdown of miR-17-5p reduces the proliferation and induces the apoptosis in SGC7901 cells by regulating the expression of Early Growth Response 2 (EGR2) [<xref ref-type="bibr" rid="CR44">44</xref>]. Similarly, miR-17-5p expression is reduced in breast cancer tissues. Overexpression of miR-17-5p inhibits cell proliferation, migration, and invasion by regulating AIB1 expression [<xref ref-type="bibr" rid="CR45">45</xref>]. Furthermore, miR-17-5p, which is upregulated in pancreatic cancer, functions as an oncogene by directly targeting RBL2 expression [<xref ref-type="bibr" rid="CR19">19</xref>]. Similar to the previous studies, we demonstrated that miR-17-5p was dramatically unregulated in LSCC tissues and LSCC cell lines. We also revealed that miR-17-5p level was correlated with LSCC T stage and TNM stage, indicating that higher expression may associate with the advanced tumor stage. Importantly, we observed that the higher level of miR-17-5p was associated with poor survival of patients with LSCC. Functionally, we further identified that miR-17-5p acted as an onco-miRNA in LSCC. Knockdown of miR-17-5p in LSCC cells reduced cell proliferation and promoted cell apoptosis in vitro and in vivo. These data suggest that miR-17-5p is a potential therapeutic target and a biomarker of LSCC.</p></sec><sec id="Sec22"><title>Conclusion</title><p id="Par36">In conclusion, our findings demonstrate that miR-17-5p is significantly increased in LSCC tissue and cell lines and may potentially be used as a diagnostic biomarker. Higher expression of miR-17-5p correlates with advanced stages of LSCC and a worse prognosis in LSCC. Dysregulation of miR-17-5p is involved in LSCC cell apoptosis and proliferation via directly targeting PIK3R1 3&#x02032;UTR and modulation of AKT activation. These findings suggest that the miR-17-5p/PIK3R1/AKT axis can be a potential therapeutic target in LSCC treatment.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>LSCC</term><def><p id="Par5">laryngeal squamous cell carcinoma</p></def></def-item><def-item><term>PI3K</term><def><p id="Par6">phosphoinositide 3-kinases</p></def></def-item><def-item><term>UTR</term><def><p id="Par7">untranslated region</p></def></def-item><def-item><term>PI3KR1</term><def><p id="Par8">phosphoinositide-3-kinase, regulatory subunit 1</p></def></def-item><def-item><term>PTEN</term><def><p id="Par9">tension homology deleted on chromosome 10</p></def></def-item><def-item><term>miRNA</term><def><p id="Par10">microRNA</p></def></def-item><def-item><term>RT-qPCR</term><def><p id="Par11">reverse transcription-quantitative polymerase chain reaction</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>The authors thank Dr. Zi-Yuan Nie for technology support.</p></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>Conception and design: JW and CS; tissues collection: SL, JD and XR; development of methodology: JW, XJ and OX; acquisition of the data: HZ and JW; analysis of data: SL, XJ and SL; writing the manuscript: JW, XJ and CS. All authors read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Availability of data and materials</title><p>Not applicable.</p></notes><notes><title>Ethics approval and consent to participate</title><p id="Par37">The present study and was authorized Ethics Committee of Second Hospital of Hebei Medical University. All patients and volunteers were anonymous and provided written informed consent. All animal studies were approved by the Institutional Animal Care Committee of Hebei Medical University.</p></notes><notes><title>Consent for publication</title><p id="Par38">Written consent was obtained from all participants.</p></notes><notes notes-type="COI-statement"><title>Competing interests</title><p id="Par39">The authors declare that they have no competing interests.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steuer</surname><given-names>CE</given-names></name><name><surname>El-Deiry</surname><given-names>M</given-names></name><name><surname>Parks</surname><given-names>JR</given-names></name><name><surname>Higgins</surname><given-names>KA</given-names></name><name><surname>Saba</surname><given-names>NF</given-names></name></person-group><article-title>An update on larynx cancer</article-title><source>CA Cancer J Clin</source><year>2017</year><volume>67</volume><issue>1</issue><fpage>31</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.3322/caac.21386</pub-id><pub-id pub-id-type="pmid">27898173</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Miller</surname><given-names>KD</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name></person-group><article-title>Cancer statistics, 2018</article-title><source>CA Cancer J Clin</source><year>2018</year><volume>68</volume><issue>1</issue><fpage>7</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.3322/caac.21442</pub-id><pub-id pub-id-type="pmid">29313949</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Popovtzer</surname><given-names>A</given-names></name><name><surname>Burnstein</surname><given-names>H</given-names></name><name><surname>Stemmer</surname><given-names>S</given-names></name><name><surname>Limon</surname><given-names>D</given-names></name><name><surname>Hili</surname><given-names>O</given-names></name><name><surname>Bachar</surname><given-names>G</given-names></name><name><surname>Sopov</surname><given-names>V</given-names></name><name><surname>Feinmesser</surname><given-names>R</given-names></name><name><surname>Groshar</surname><given-names>D</given-names></name><name><surname>Shvero</surname><given-names>J</given-names></name></person-group><article-title>Phase II organ-preservation trial: concurrent cisplatin and radiotherapy for advanced laryngeal cancer after response to docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy</article-title><source>Head Neck</source><year>2017</year><volume>39</volume><issue>2</issue><fpage>227</fpage><lpage>233</lpage><pub-id pub-id-type="doi">10.1002/hed.24571</pub-id><pub-id pub-id-type="pmid">27556178</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forastiere</surname><given-names>AA</given-names></name><name><surname>Goepfert</surname><given-names>H</given-names></name><name><surname>Maor</surname><given-names>M</given-names></name><name><surname>Pajak</surname><given-names>TF</given-names></name><name><surname>Weber</surname><given-names>R</given-names></name><name><surname>Morrison</surname><given-names>W</given-names></name><name><surname>Glisson</surname><given-names>B</given-names></name><name><surname>Trotti</surname><given-names>A</given-names></name><name><surname>Ridge</surname><given-names>JA</given-names></name><name><surname>Chao</surname><given-names>C</given-names></name><etal/></person-group><article-title>Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer</article-title><source>N Engl J Med</source><year>2003</year><volume>349</volume><issue>22</issue><fpage>2091</fpage><lpage>2098</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa031317</pub-id><pub-id pub-id-type="pmid">14645636</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffman</surname><given-names>HT</given-names></name><name><surname>Porter</surname><given-names>K</given-names></name><name><surname>Karnell</surname><given-names>LH</given-names></name><name><surname>Cooper</surname><given-names>JS</given-names></name><name><surname>Weber</surname><given-names>RS</given-names></name><name><surname>Langer</surname><given-names>CJ</given-names></name><name><surname>Ang</surname><given-names>KK</given-names></name><name><surname>Gay</surname><given-names>G</given-names></name><name><surname>Stewart</surname><given-names>A</given-names></name><name><surname>Robinson</surname><given-names>RA</given-names></name></person-group><article-title>Laryngeal cancer in the United States: changes in demographics, patterns of care, and survival</article-title><source>Laryngoscope</source><year>2006</year><volume>116</volume><issue>9 Pt 2 Suppl 111</issue><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1097/01.mlg.0000236095.97947.26</pub-id><pub-id pub-id-type="pmid">16946667</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartel</surname><given-names>DP</given-names></name></person-group><article-title>MicroRNAs: target recognition and regulatory functions</article-title><source>Cell</source><year>2009</year><volume>136</volume><issue>2</issue><fpage>215</fpage><lpage>233</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2009.01.002</pub-id><pub-id pub-id-type="pmid">19167326</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>SY</given-names></name><name><surname>Gao</surname><given-names>YM</given-names></name><name><surname>Liu</surname><given-names>YF</given-names></name><name><surname>Liu</surname><given-names>YB</given-names></name><name><surname>Zhao</surname><given-names>ZG</given-names></name><name><surname>Yang</surname><given-names>K</given-names></name></person-group><article-title>MicroRNAs as oncogenes or tumour suppressors in oesophageal cancer: potential biomarkers and therapeutic targets</article-title><source>Cell Prolif</source><year>2014</year><volume>47</volume><issue>4</issue><fpage>277</fpage><lpage>286</lpage><pub-id pub-id-type="doi">10.1111/cpr.12109</pub-id><pub-id pub-id-type="pmid">24909356</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Lin</surname><given-names>C</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Jin</surname><given-names>D</given-names></name></person-group><article-title>Down-regulation of MiR-206 promotes proliferation and invasion of laryngeal cancer by regulating VEGF expression</article-title><source>Anticancer Res</source><year>2011</year><volume>31</volume><issue>11</issue><fpage>3859</fpage><lpage>3863</lpage><pub-id pub-id-type="pmid">22110210</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Cao</surname><given-names>H</given-names></name></person-group><article-title>MicroRNA-143-3p suppresses cell growth and invasion in laryngeal squamous cell carcinoma via targeting the k-Ras/Raf/MEK/ERK signaling pathway</article-title><source>Int J Oncol</source><year>2019</year><volume>54</volume><issue>2</issue><fpage>689</fpage><lpage>701</lpage><pub-id pub-id-type="pmid">30535502</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niu</surname><given-names>JT</given-names></name><name><surname>Zhang</surname><given-names>LJ</given-names></name><name><surname>Huang</surname><given-names>YW</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Jiang</surname><given-names>N</given-names></name><name><surname>Niu</surname><given-names>YJ</given-names></name></person-group><article-title>MiR-154 inhibits the growth of laryngeal squamous cell carcinoma by targeting GALNT7</article-title><source>Biochem Cell Biol</source><year>2018</year><volume>96</volume><issue>6</issue><fpage>752</fpage><lpage>760</lpage><pub-id pub-id-type="doi">10.1139/bcb-2018-0047</pub-id><pub-id pub-id-type="pmid">29874469</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>JX</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Jia</surname><given-names>XJ</given-names></name><name><surname>Liu</surname><given-names>SX</given-names></name><name><surname>Dong</surname><given-names>JH</given-names></name><name><surname>Ren</surname><given-names>XM</given-names></name><name><surname>Xu</surname><given-names>O</given-names></name><name><surname>Zhang</surname><given-names>HZ</given-names></name><name><surname>Duan</surname><given-names>HJ</given-names></name><name><surname>Shan</surname><given-names>CG</given-names></name></person-group><article-title>Upregulation of circFLNA contributes to laryngeal squamous cell carcinoma migration by circFLNA-miR-486-3p-FLNA axis</article-title><source>Cancer Cell Int</source><year>2019</year><volume>19</volume><fpage>196</fpage><pub-id pub-id-type="doi">10.1186/s12935-019-0924-9</pub-id><pub-id pub-id-type="pmid">31384171</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yungang</surname><given-names>W</given-names></name><name><surname>Xiaoyu</surname><given-names>L</given-names></name><name><surname>Pang</surname><given-names>T</given-names></name><name><surname>Wenming</surname><given-names>L</given-names></name><name><surname>Pan</surname><given-names>X</given-names></name></person-group><article-title>miR-370 targeted FoxM1 functions as a tumor suppressor in laryngeal squamous cell carcinoma (LSCC)</article-title><source>Biomed Pharmacother</source><year>2014</year><volume>68</volume><issue>2</issue><fpage>149</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.1016/j.biopha.2013.08.008</pub-id><pub-id pub-id-type="pmid">24055400</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>S</given-names></name><name><surname>Ge</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Han</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>M</given-names></name></person-group><article-title>MiR-613 suppressed the laryngeal squamous cell carcinoma progression through regulating PDK1</article-title><source>J Cell Biochem</source><year>2018</year><volume>119</volume><issue>7</issue><fpage>5118</fpage><lpage>5125</lpage><pub-id pub-id-type="doi">10.1002/jcb.26468</pub-id><pub-id pub-id-type="pmid">29091303</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>HL</given-names></name><name><surname>Peng</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>HF</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name></person-group><article-title>miR-1297 mediates PTEN expression and contributes to cell progression in LSCC</article-title><source>Biochem Biophys Res Commun</source><year>2012</year><volume>427</volume><issue>2</issue><fpage>254</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2012.09.025</pub-id><pub-id pub-id-type="pmid">22995297</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shuang</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name></person-group><article-title>MicroRNA503 serves an oncogenic role in laryngeal squamous cell carcinoma via targeting programmed cell death protein 4</article-title><source>Mol Med Rep</source><year>2017</year><volume>16</volume><issue>4</issue><fpage>5249</fpage><lpage>5256</lpage><pub-id pub-id-type="doi">10.3892/mmr.2017.7278</pub-id><pub-id pub-id-type="pmid">28849168</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>L</given-names></name><name><surname>Tang</surname><given-names>M</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Jiang</surname><given-names>B</given-names></name><name><surname>Wei</surname><given-names>Y</given-names></name><name><surname>Qian</surname><given-names>H</given-names></name><name><surname>Lu</surname><given-names>X</given-names></name></person-group><article-title>MiR-143-3p suppresses cell proliferation, migration, and invasion by targeting Melanoma-Associated Antigen A9 in laryngeal squamous cell carcinoma</article-title><source>J Cell Biochem</source><year>2018</year><volume>120</volume><fpage>1254</fpage><lpage>1257</lpage></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhong</surname><given-names>G</given-names></name><name><surname>Xiong</surname><given-names>X</given-names></name></person-group><article-title>miR-205 promotes proliferation and invasion of laryngeal squamous cell carcinoma by suppressing CDK2AP1 expression</article-title><source>Biol Res</source><year>2015</year><volume>48</volume><fpage>60</fpage><pub-id pub-id-type="doi">10.1186/s40659-015-0052-5</pub-id><pub-id pub-id-type="pmid">26515287</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Jiang</surname><given-names>M</given-names></name><name><surname>Yuan</surname><given-names>W</given-names></name><name><surname>Tang</surname><given-names>H</given-names></name></person-group><article-title>miR-17-5p as a novel prognostic marker for hepatocellular carcinoma</article-title><source>J Invest Surg</source><year>2012</year><volume>25</volume><issue>3</issue><fpage>156</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.3109/08941939.2011.618523</pub-id><pub-id pub-id-type="pmid">22583011</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Gu</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Peng</surname><given-names>C</given-names></name><name><surname>Shi</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Wei</surname><given-names>G</given-names></name><name><surname>Ge</surname><given-names>O</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><etal/></person-group><article-title>MiR-17-5p enhances pancreatic cancer proliferation by altering cell cycle profiles via disruption of RBL2/E2F4-repressing complexes</article-title><source>Cancer Lett</source><year>2018</year><volume>412</volume><fpage>59</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2017.09.044</pub-id><pub-id pub-id-type="pmid">28987387</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Lai</surname><given-names>Y</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Bi</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Yao</surname><given-names>C</given-names></name><name><surname>Lv</surname><given-names>W</given-names></name><name><surname>Chang</surname><given-names>G</given-names></name><etal/></person-group><article-title>miR-17-5p suppresses cell proliferation and invasion by targeting ETV1 in triple-negative breast cancer</article-title><source>BMC Cancer</source><year>2017</year><volume>17</volume><issue>1</issue><fpage>745</fpage><pub-id pub-id-type="doi">10.1186/s12885-017-3674-x</pub-id><pub-id pub-id-type="pmid">29126392</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gong</surname><given-names>AY</given-names></name><name><surname>Eischeid</surname><given-names>AN</given-names></name><name><surname>Xiao</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>ZY</given-names></name><name><surname>Young</surname><given-names>CY</given-names></name><name><surname>Chen</surname><given-names>XM</given-names></name></person-group><article-title>miR-17-5p targets the p300/CBP-associated factor and modulates androgen receptor transcriptional activity in cultured prostate cancer cells</article-title><source>BMC Cancer</source><year>2012</year><volume>12</volume><fpage>492</fpage><pub-id pub-id-type="doi">10.1186/1471-2407-12-492</pub-id><pub-id pub-id-type="pmid">23095762</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Q</given-names></name><name><surname>Luo</surname><given-names>G</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Zhu</surname><given-names>F</given-names></name><name><surname>An</surname><given-names>Y</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Fan</surname><given-names>D</given-names></name></person-group><article-title>miR-17-5p promotes proliferation by targeting SOCS6 in gastric cancer cells</article-title><source>FEBS Lett</source><year>2014</year><volume>588</volume><issue>12</issue><fpage>2055</fpage><lpage>2062</lpage><pub-id pub-id-type="doi">10.1016/j.febslet.2014.04.036</pub-id><pub-id pub-id-type="pmid">24801601</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Samuels</surname><given-names>Y</given-names></name><name><surname>Ericson</surname><given-names>K</given-names></name></person-group><article-title>Oncogenic PI3K and its role in cancer</article-title><source>Curr Opin Oncol</source><year>2006</year><volume>18</volume><issue>1</issue><fpage>77</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1097/01.cco.0000198021.99347.b9</pub-id><pub-id pub-id-type="pmid">16357568</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Polivka</surname><given-names>J</given-names></name><name><surname>Janku</surname><given-names>F</given-names></name></person-group><article-title>Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway</article-title><source>Pharmacol Ther</source><year>2014</year><volume>142</volume><issue>2</issue><fpage>164</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1016/j.pharmthera.2013.12.004</pub-id><pub-id pub-id-type="pmid">24333502</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>TL</given-names></name><name><surname>Cantley</surname><given-names>LC</given-names></name></person-group><article-title>PI3K pathway alterations in cancer: variations on a theme</article-title><source>Oncogene</source><year>2008</year><volume>27</volume><issue>41</issue><fpage>5497</fpage><lpage>5510</lpage><pub-id pub-id-type="doi">10.1038/onc.2008.245</pub-id><pub-id pub-id-type="pmid">18794884</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thorpe</surname><given-names>LM</given-names></name><name><surname>Spangle</surname><given-names>JM</given-names></name><name><surname>Ohlson</surname><given-names>CE</given-names></name><name><surname>Cheng</surname><given-names>HL</given-names></name><name><surname>Roberts</surname><given-names>TM</given-names></name><name><surname>Cantley</surname><given-names>LC</given-names></name><name><surname>Zhao</surname><given-names>JJ</given-names></name></person-group><article-title>PI3K-p110 alpha mediates the oncogenic activity induced by loss of the novel tumor suppressor PI3K-p85 alpha</article-title><source>Proc Natl Acad Sci USA</source><year>2017</year><volume>114</volume><issue>27</issue><fpage>7095</fpage><lpage>7100</lpage><pub-id pub-id-type="doi">10.1073/pnas.1704706114</pub-id><pub-id pub-id-type="pmid">28630349</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ai</surname><given-names>XJ</given-names></name><name><surname>Xiang</surname><given-names>L</given-names></name><name><surname>Huang</surname><given-names>Z</given-names></name><name><surname>Zhou</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Jiang</surname><given-names>TP</given-names></name></person-group><article-title>Overexpression of PIK3R1 promotes hepatocellular carcinoma progression</article-title><source>Biol Res</source><year>2018</year><volume>51</volume><fpage>52</fpage><pub-id pub-id-type="doi">10.1186/s40659-018-0202-7</pub-id><pub-id pub-id-type="pmid">30497511</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>YC</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Xu</surname><given-names>A</given-names></name><name><surname>Dong</surname><given-names>P</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>FD</given-names></name><name><surname>Wang</surname><given-names>HF</given-names></name><name><surname>Xu</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>YQ</given-names></name><etal/></person-group><article-title>PIK3R1 negatively regulates the epithelial-mesenchymal transition and stem-like phenotype of renal cancer cells through the AKT/GSK3 beta/CTNNB1 signaling pathway</article-title><source>Sci Rep</source><year>2015</year><volume>5</volume><fpage>8997</fpage><pub-id pub-id-type="doi">10.1038/srep08997</pub-id><pub-id pub-id-type="pmid">25757764</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>XR</given-names></name><name><surname>Mak</surname><given-names>VCY</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Wong</surname><given-names>ESY</given-names></name><name><surname>Sharma</surname><given-names>R</given-names></name><name><surname>Lu</surname><given-names>YL</given-names></name><name><surname>Cheung</surname><given-names>ANY</given-names></name><name><surname>Mills</surname><given-names>GB</given-names></name><name><surname>Cheung</surname><given-names>LWT</given-names></name></person-group><article-title>Deregulated Gab2 phosphorylation mediates aberrant AKT and STAT3 signaling upon PIK3R1 loss in ovarian cancer</article-title><source>Nat Commun</source><year>2019</year><volume>10</volume><fpage>716</fpage><pub-id pub-id-type="doi">10.1038/s41467-019-08574-7</pub-id><pub-id pub-id-type="pmid">30755611</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>QM</given-names></name><name><surname>Lei</surname><given-names>FM</given-names></name><name><surname>Chang</surname><given-names>YG</given-names></name><name><surname>Gao</surname><given-names>ZY</given-names></name><name><surname>Wang</surname><given-names>YZ</given-names></name><name><surname>Gao</surname><given-names>QK</given-names></name><name><surname>Niu</surname><given-names>PF</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name></person-group><article-title>An oncogenic gene, SNRPA1, regulates PIK3R1, VEGFC, MKI67, CDK1 and other genes in colorectal cancer</article-title><source>Biomed Pharmacother</source><year>2019</year><volume>117</volume><fpage>109076</fpage><pub-id pub-id-type="doi">10.1016/j.biopha.2019.109076</pub-id><pub-id pub-id-type="pmid">31203132</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nie</surname><given-names>ZY</given-names></name><name><surname>Liu</surname><given-names>XJ</given-names></name><name><surname>Zhan</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>MH</given-names></name><name><surname>Zhang</surname><given-names>XY</given-names></name><name><surname>Li</surname><given-names>ZY</given-names></name><name><surname>Lu</surname><given-names>YQ</given-names></name><name><surname>Luo</surname><given-names>JM</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name></person-group><article-title>miR-140-5p induces cell apoptosis and decreases Warburg effect in chronic myeloid leukemia by targeting SIX1</article-title><source>Biosci Rep</source><year>2019</year><pub-id pub-id-type="doi">10.1042/BSR20190150</pub-id><pub-id pub-id-type="pmid">31815282</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hennessy</surname><given-names>BT</given-names></name><name><surname>Smith</surname><given-names>DL</given-names></name><name><surname>Ram</surname><given-names>PT</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Mills</surname><given-names>GB</given-names></name></person-group><article-title>Exploiting the PI3K/AKT pathway for cancer drug discovery</article-title><source>Nat Rev Drug Discov</source><year>2005</year><volume>4</volume><issue>12</issue><fpage>988</fpage><lpage>1004</lpage><pub-id pub-id-type="doi">10.1038/nrd1902</pub-id><pub-id pub-id-type="pmid">16341064</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>McIlroy</surname><given-names>J</given-names></name><name><surname>Rordorf-Nikolic</surname><given-names>T</given-names></name><name><surname>Orr</surname><given-names>GA</given-names></name><name><surname>Backer</surname><given-names>JM</given-names></name></person-group><article-title>Regulation of the p85/p110 phosphatidylinositol 3&#x02032;-kinase: stabilization and inhibition of the p110alpha catalytic subunit by the p85 regulatory subunit</article-title><source>Mol Cell Biol</source><year>1998</year><volume>18</volume><issue>3</issue><fpage>1379</fpage><lpage>1387</lpage><pub-id pub-id-type="doi">10.1128/MCB.18.3.1379</pub-id><pub-id pub-id-type="pmid">9488453</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taniguchi</surname><given-names>CM</given-names></name><name><surname>Winnay</surname><given-names>J</given-names></name><name><surname>Kondo</surname><given-names>T</given-names></name><name><surname>Bronson</surname><given-names>RT</given-names></name><name><surname>Guimaraes</surname><given-names>AR</given-names></name><name><surname>Aleman</surname><given-names>JO</given-names></name><name><surname>Luo</surname><given-names>J</given-names></name><name><surname>Stephanopoulos</surname><given-names>G</given-names></name><name><surname>Weissleder</surname><given-names>R</given-names></name><name><surname>Cantley</surname><given-names>LC</given-names></name><etal/></person-group><article-title>The phosphoinositide 3-kinase regulatory subunit p85alpha can exert tumor suppressor properties through negative regulation of growth factor signaling</article-title><source>Cancer Res</source><year>2010</year><volume>70</volume><issue>13</issue><fpage>5305</fpage><lpage>5315</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-09-3399</pub-id><pub-id pub-id-type="pmid">20530665</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cizkova</surname><given-names>M</given-names></name><name><surname>Vacher</surname><given-names>S</given-names></name><name><surname>Meseure</surname><given-names>D</given-names></name><name><surname>Trassard</surname><given-names>M</given-names></name><name><surname>Susini</surname><given-names>A</given-names></name><name><surname>Mlcuchova</surname><given-names>D</given-names></name><name><surname>Callens</surname><given-names>C</given-names></name><name><surname>Rouleau</surname><given-names>E</given-names></name><name><surname>Spyratos</surname><given-names>F</given-names></name><name><surname>Lidereau</surname><given-names>R</given-names></name><etal/></person-group><article-title>PIK3R1 underexpression is an independent prognostic marker in breast cancer</article-title><source>BMC Cancer</source><year>2013</year><volume>13</volume><fpage>545</fpage><pub-id pub-id-type="doi">10.1186/1471-2407-13-545</pub-id><pub-id pub-id-type="pmid">24229379</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Lemon</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>PY</given-names></name><name><surname>Yi</surname><given-names>Y</given-names></name><name><surname>Morrison</surname><given-names>C</given-names></name><name><surname>Yang</surname><given-names>P</given-names></name><name><surname>Sun</surname><given-names>Z</given-names></name><name><surname>Szoke</surname><given-names>J</given-names></name><name><surname>Gerald</surname><given-names>WL</given-names></name><name><surname>Watson</surname><given-names>M</given-names></name><etal/></person-group><article-title>A gene expression signature predicts survival of patients with stage I non-small cell lung cancer</article-title><source>PLoS Med</source><year>2006</year><volume>3</volume><issue>12</issue><fpage>e467</fpage><pub-id pub-id-type="doi">10.1371/journal.pmed.0030467</pub-id><pub-id pub-id-type="pmid">17194181</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uchino</surname><given-names>M</given-names></name><name><surname>Kojima</surname><given-names>H</given-names></name><name><surname>Wada</surname><given-names>K</given-names></name><name><surname>Imada</surname><given-names>M</given-names></name><name><surname>Onoda</surname><given-names>F</given-names></name><name><surname>Satofuka</surname><given-names>H</given-names></name><name><surname>Utsugi</surname><given-names>T</given-names></name><name><surname>Murakami</surname><given-names>Y</given-names></name></person-group><article-title>Nuclear beta-catenin and CD44 upregulation characterize invasive cell populations in non-aggressive MCF-7 breast cancer cells</article-title><source>BMC Cancer</source><year>2010</year><volume>10</volume><fpage>414</fpage><pub-id pub-id-type="doi">10.1186/1471-2407-10-414</pub-id><pub-id pub-id-type="pmid">20696077</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>M</given-names></name><name><surname>Hillmann</surname><given-names>P</given-names></name><name><surname>Hofmann</surname><given-names>BT</given-names></name><name><surname>Hart</surname><given-names>JR</given-names></name><name><surname>Vogt</surname><given-names>PK</given-names></name></person-group><article-title>Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha</article-title><source>Proc Natl Acad Sci USA</source><year>2010</year><volume>107</volume><issue>35</issue><fpage>15547</fpage><lpage>15552</lpage><pub-id pub-id-type="doi">10.1073/pnas.1009652107</pub-id><pub-id pub-id-type="pmid">20713702</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>TF</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>K</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Yan</surname><given-names>Q</given-names></name></person-group><article-title>Long noncoding RNA NEAT1 promotes the growth of gastric cancer cells by regulating miR-497-5p/PIK3R1 axis</article-title><source>Eur Rev Med Pharmacol Sci</source><year>2019</year><volume>23</volume><issue>16</issue><fpage>6914</fpage><lpage>6926</lpage><pub-id pub-id-type="pmid">31486491</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Ouyang</surname><given-names>TL</given-names></name><name><surname>Lu</surname><given-names>N</given-names></name><name><surname>Lu</surname><given-names>JF</given-names></name><name><surname>Shen</surname><given-names>YT</given-names></name><name><surname>Bai</surname><given-names>YF</given-names></name><name><surname>Xie</surname><given-names>XY</given-names></name><name><surname>Ge</surname><given-names>QY</given-names></name></person-group><article-title>MiR-486-5p serves as a good biomarker in nonsmall cell lung cancer and suppresses cell growth with the involvement of a target PIK3R1</article-title><source>Front Genet</source><year>2019</year><volume>10</volume><fpage>688</fpage><pub-id pub-id-type="doi">10.3389/fgene.2019.00688</pub-id><pub-id pub-id-type="pmid">31402930</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Han</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>YB</given-names></name><name><surname>Sun</surname><given-names>YF</given-names></name><name><surname>Zou</surname><given-names>MY</given-names></name><name><surname>Fu</surname><given-names>YL</given-names></name><name><surname>Peng</surname><given-names>XL</given-names></name></person-group><article-title>Upregulated gga-miR-16-5p inhibits the proliferation cycle and promotes the apoptosis of MG-infected DF-1 cells by repressing PIK3R1-mediated the PI3K/Akt/NF-B pathway to exert anti-inflammatory effect</article-title><source>Int J Mol Sci</source><year>2019</year><volume>20</volume><issue>5</issue><fpage>1036</fpage><pub-id pub-id-type="doi">10.3390/ijms20051036</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Zhu</surname><given-names>YB</given-names></name><name><surname>Zhang</surname><given-names>HF</given-names></name><name><surname>Ma</surname><given-names>GJ</given-names></name><name><surname>Wu</surname><given-names>GF</given-names></name><name><surname>Xiang</surname><given-names>AQ</given-names></name><name><surname>Shi</surname><given-names>XE</given-names></name><name><surname>Yang</surname><given-names>GS</given-names></name><name><surname>Sun</surname><given-names>SD</given-names></name></person-group><article-title>MicroRNA-106a-5p inhibited C2C12 myogenesis via targeting PIK3R1 and modulating the PI3K/AKT signaling</article-title><source>Genes</source><year>2018</year><volume>9</volume><issue>7</issue><fpage>333</fpage><pub-id pub-id-type="doi">10.3390/genes9070333</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>AL</given-names></name><name><surname>Luo</surname><given-names>RY</given-names></name><name><surname>Ruan</surname><given-names>P</given-names></name></person-group><article-title>miR-495 promotes apoptosis and inhibits proliferation in endometrial cells via targeting PIK3R1</article-title><source>Pathol Res Pract</source><year>2019</year><volume>215</volume><issue>3</issue><fpage>594</fpage><lpage>599</lpage><pub-id pub-id-type="doi">10.1016/j.prp.2019.01.020</pub-id><pub-id pub-id-type="pmid">30691859</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>P</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Yan</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name></person-group><article-title>MicroRNA-17-5p promotes gastric cancer proliferation, migration and invasion by directly targeting early growth response 2</article-title><source>Am J Cancer Res</source><year>2016</year><volume>6</volume><issue>9</issue><fpage>2010</fpage><lpage>2020</lpage><pub-id pub-id-type="pmid">27725906</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Bian</surname><given-names>C</given-names></name><name><surname>Liao</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>RC</given-names></name></person-group><article-title>miR-17-5p promotes human breast cancer cell migration and invasion through suppression of HBP1</article-title><source>Breast Cancer Res Treat</source><year>2011</year><volume>126</volume><issue>3</issue><fpage>565</fpage><lpage>575</lpage><pub-id pub-id-type="doi">10.1007/s10549-010-0954-4</pub-id><pub-id pub-id-type="pmid">20505989</pub-id></element-citation></ref></ref-list></back></article>